Immunai

Immunology based personalized disease treatments

Analytics, Data, Drug Development

Artificial Intelligence Deep Learning Machine Learning

Business Overview

Decoding the immune system to improve health.

Comprehensively mapping the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes.

Cutting-edge biology coupled with machine-learning to unravel the immune system. We are curating the largest proprietary data-set of multi-omic, immune-centric analyses of peripheral tissues. Our advanced analytics and data-visualization interface allows researchers to comprehensively view and interrogate data, and derive novel conclusions on the underlying mechanisms of disease. With a comprehensive view of the immune system, clinicians are better equipped to personalize and optimize treatment choices for each patient, and maximize positive outcomes. Immunai’s mission is to transform immunology by pioneering single-cell technologies coupled with the most cutting-edge AI methods.

Operating Status

Active

Founded

January 2019

Employees

Business model

B2B

Offering type

Software

Funding stage

Series A

Business stage

Product Development

Total funding

$80 Million

Investors

Catalio Capital Management, Dexcel Pharma, Duquesne Family, Gefen Capital, Meron Capital, Schusterman Family Investments, TLV Partners, Viola Ventures

Sectors

Analytics, Data, Drug Development, Healthcare, Immunology, Personalized Treatment

Founders

Luis Voloch

CTO

AI Expert

Noam Solomon

CEO

AI Expert

Danny Wells

Scientific Founder

Ansuman Satpathy

Scientific Founder

Dan Littman

Scientific Founder

Board Members and Advisors

Dan Littman

Advisor

Jimmie Ye

Advisor

Matthew Hellmann

Advisor

Michael Kalos

Advisor

Rahul Satija

Advisor

Regina Barzilay

Advisor

Kimary Kulig

Advisor

Larry Marton

Advisor

Laurence Nore

Advisor

Michael Aberman

Advisor

Steven Averbuch

Advisor

Funding Rounds

New wpDataTable

investment_rounds_post_date	investment_rounds_post_date_gmt	investment_rounds_meta_investment_rounds_investment_amount	investment_rounds_meta_investment_rounds_startup_tag
2020	May 2020 05:16 PM	20.0	4466
2021	Feb 2021 05:09 PM	60.0	4466

Date Announced

Funding Round

Amount Raised

Investors

February 2021

Series A

$60 M

Catalio Capital Management, Dexcel Pharma, Duquesne Family, Schusterman Family Investments, TLV Partners, Viola Ventures

May 2020

Seed

$20 M

TLV Partners, Viola Ventures

Exit Events and Acquisitions

Date Announced

Transaction

Consideration

Target

Acquirer

March 2021

Acquisition

Dropprint Genomics

Immunai

AI Technology Stack

AI employees

AI application

Vertical AI

AI types

Artificial Intelligence, Deep Learning, Machine Learning

ML types

Supervised Learning, Unsupervised Learning

AI tools

Docker, Keras, Pytorch, Scikit-Learn, TensorFlow

Coding

Python, R

Cloud provider

Amazon Web Services, Google Cloud AI

Patents

A system for predicting treatment outcomes based upon genetic imputation

WO2021035023A1

Application

System for predicting treatment outcomes based upon genetic imputation

US20210057107A1

Application

Research

Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis

Vα24-invariant natural killer T (NKT) cells have shown potent anti-tumor properties in murine tumor models and have been linked to favorable outcomes in patients with cancer. However, low numbers of these cells in humans have hindered their clinical applications. Here we report interim results from all three patients enrolled on...

Nature Medicine
12/10/2020

Multi-Clonal Live SARS-CoV-2 In Vitro Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors

The interactions between antibodies, SARS-CoV-2 and immune cells contribute to the pathogenesis of COVID-19 and protective immunity. To understand the differences between antibody responses in mild versus severe cases of COVID-19, we analyzed the B cell responses in patients 1.5 months post SARS-CoV-2 infection. Severe and not mild infection correlated...

BioRxiv
06/10/2020

Clonal replacement of tumor-specific T cells following PD-1 blockade

Immunotherapies that block inhibitory checkpoint receptors on T cells have transformed the clinical care of patients with cancer1. However, whether the T cell response to checkpoint blockade relies on reinvigoration of pre-existing tumor-infiltrating lymphocytes or on recruitment of novel T cells remains unclear2,3,4. Here we performed paired single-cell RNA and...